Could a pneumonia shot save myeloma patients from deadly infections?

NCT ID NCT07154537

Ongoing Prevention Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

Multiple myeloma patients are at high risk for serious bacterial infections like pneumonia. This study at National Taiwan University Hospital will give 101 patients either one or two doses of the PCV13 pneumonia vaccine to see which schedule is safer and boosts immunity better. Researchers hope to find a way to prevent these often-deadly infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 13-valent pneumococcal conjugate vaccine (PCV13)
What this could lead to: If successful, this could show that a simple vaccine schedule helps protect multiple myeloma patients from life-threatening pneumonia and blood infections.
What could go wrong: This is a small, single-hospital study. Earlier research suggests these vaccines may not work well in multiple myeloma patients, so the benefit may be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

National Taiwan University Hospital

Taipei, Taipei, 100226, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.